2025 AMCP Nexus Congress

BioCryst will attend the 2025 AMCP Nexus Congress from Oct 27-30, 2025.

Filter
  • Burden of Treatment for Pediatric Patients (Aged Less Than 12 Years) With Hereditary Angioedema and Their Caregivers
    HAEA National Summit | 2025 | Hereditary Angioedema (HAE)
  • Patient Perspectives on the Importance of HAE Treatments
    HAEA National Summit | 2025 | Hereditary Angioedema (HAE)
  • HAE Attack Rates in Pediatric Patients 2 to <12 Years of Age with Prophylactic Berotralstat: Results from Interim Analysis of APeX-P
    HAEA National Summit | 2025 | Hereditary Angioedema (HAE)
  • Berotralstat Use Reduced Number of HAE Attacks Requiring Treatment or Professional Care in Pediatric Patients: Interim Results From APeX-P
    EAACI | 2025 | Hereditary Angioedema (HAE)
  • Assessment of the Effectiveness and Tolerability of Berotralstat for Long-term Prophylaxis in Hereditary Angioedema: Findings from the Berolife Study
    EAACI | 2025 | Hereditary Angioedema (HAE)
  • Patients With HAE Report Positive Perceptions Following Berotralstat Treatment: Results From a Focus Group
    EAACI | 2025 | Hereditary Angioedema (HAE)
  • Impact of Berotralstat on Quality of Life in Patients with Hereditary Angioedema
    EAACI | 2025 | Hereditary Angioedema (HAE)
  • Berotralstat for the Prevention of Hereditary Angioedema Attacks: Results from the Italian Expanded Access Programme
    C1-INH Def Wkshp | 2025 | Hereditary Angioedema (HAE)
  • Tolerability and Effectiveness of Berotralstat for Prophylaxis in Adolescents with Hereditary Angioedema: Subgroup Analysis of the Berolife Study
    C1-INH Def Wkshp | 2025 | Hereditary Angioedema (HAE)
  • Reduction in Percentage of Days With Angioedema Symptoms Among Young Children Initiating Berotralstat: Interim Results From APeX-P
    C1-INH Def Wkshp | 2025 | Hereditary Angioedema (HAE)
Load more >>